PapersFlow Research Brief
Cardiac Valve Diseases and Treatments
Research Guide
What is Cardiac Valve Diseases and Treatments?
Cardiac valve diseases and treatments encompass the management of valvular heart disease, emphasizing transcatheter and surgical aortic-valve replacement, echocardiography evaluation of valvular regurgitation, guidelines for prosthetic valve assessment, and risk models for cardiac surgery outcomes.
The field includes 172,738 works focused on valvular heart disease management. Key areas cover transcatheter aortic-valve replacement (TAVR), surgical aortic-valve replacement (SAVR), and echocardiography for valvular regurgitation and prosthetic valve evaluation. Growth data over the past 5 years is not available.
Topic Hierarchy
Research Sub-Topics
Transcatheter Aortic-Valve Replacement
This sub-topic investigates TAVR procedures, device innovations, patient selection, and long-term outcomes in high-risk aortic stenosis patients. Researchers compare TAVR efficacy against surgery and study complications like paravalvular leak.
Surgical Aortic-Valve Replacement
This sub-topic covers surgical techniques, bioprosthetic and mechanical valve choices, and risk stratification models like EuroSCORE for aortic valve surgery. Researchers analyze perioperative outcomes and durability of prostheses.
Valvular Regurgitation Echocardiography
This sub-topic focuses on echocardiographic quantification of mitral and aortic regurgitation severity using vena contracta, PISA, and 3D imaging. Researchers develop and validate guidelines for accurate assessment and prognosis.
Prosthetic Valve Assessment
This sub-topic examines echocardiography protocols for evaluating prosthetic valve function, thrombosis, and dysfunction per guidelines. Researchers study multimodality imaging including CT and Doppler parameters.
Cardiac Surgery Risk Models
This sub-topic explores predictive models like EuroSCORE II and STS score for outcomes in valve surgery, incorporating comorbidities and procedural risks. Researchers validate and refine models for personalized decision-making.
Why It Matters
Transcatheter aortic-valve implantation reduced death rates from any cause compared to standard therapy in patients with severe aortic stenosis unsuitable for surgery, as shown in the PARTNER trial by Leon et al. (2010) with 7011 citations. In high-risk patients, TAVR achieved similar 1-year survival rates to SAVR despite differing periprocedural risks, per Smith et al. (2011). Guidelines like Baumgartner et al. (2017) provide evidence-based management for aortic stenosis, mitral regurgitation, and tricuspid conditions, influencing clinical practice across cardiology centers. Recent funding, such as $26 million to Cedars-Sinai for comparing open-heart surgery and minimally invasive procedures in congenital heart valve disease, supports outcome improvements. Startups like CroíValve and Cardiac Dimensions received EIC and $53M funding for transcatheter mitral valve technologies targeting regurgitation.
Reading Guide
Where to Start
"ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease" by Bonow et al. (2006), as it provides foundational management strategies cited 8502 times, serving as an entry point before advanced TAVR trials.
Key Papers Explained
Lang et al. (2005) established baseline echocardiography chamber quantification standards (11253 citations), updated by Lang et al. (2015) (17399 citations) to incorporate technological advances. Bonow et al. (2006) delivered ACC/AHA guidelines (8502 citations) for valvular management, evolved into Baumgartner et al. (2017) ESC/EACTS guidelines (6240 citations). Leon et al. (2010) introduced TAVR efficacy in inoperable patients (7011 citations), extended by Smith et al. (2011) comparing TAVR to SAVR in high-risk cases (6206 citations).
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
2025 ESC/EACTS Guidelines by Praz et al. emphasize Heart Team and Valve Centre approaches, with sections on evidence gaps. Pocket Guidelines on Valvular Heart Disease outline key messages for aortic, mitral, and tricuspid interventions. Funding to CroíValve, Cardiac Dimensions ($53M), and Cedars-Sinai ($26M) advances transcatheter mitral technologies and congenital treatments.
Papers at a Glance
In the News
CroíValve awarded EIC Accelerator funding to advance ...
**EIT Health-supported start-up** **CroíValve** **has been awarded funding from Horizon Europe’s**** European Innovation Council (EIC) Accelerator Programme****, marking a major milestone in the co...
Leaflet Solutions Inc. announces the closing of a CAD 5.73M
Founded in 2024, Leaflet Solutions Inc. is dedicated to increasing accessibility to transcatheter mitral valve replacements for patients suffering from moderate to severe
Cardiac Dimensions lands $53M for heart valve technology
Cardiac Dimensions is targeting a condition called mitral valve regurgitation , which involves the leakage of blood through the heart’s mitral valve during the contraction of the left ventricle. Th...
Cedars-Sinai Awarded $26M to Study Heart Valve Disease Treatments
Cedars-Sinai has been awarded $26 million to study whether open-heart surgery or a minimally invasive procedure has better outcomes in people born with a common heart condition.
Bioengineered heart valves for personalized therapy: advances in manufacturing and clinical challenges
REVIEW article Front. Bioeng. Biotechnol., 12 January 2026 Sec. Tissue Engineering and Regenerative Medicine Volume 13 - 2025 | https://doi.org/10.3389/fbioe.2025.1714534
Code & Tools
PanEcho is a view-agnostic, multi-task model that performs 39 reporting tasks from echocardiogram videos. The model consists of an image encoder, t...
The Texas TriValve 1.1 is a second patient-specific, high fidelity finite element model of the human tricuspid valve. We follow the same approach a...
`svFSI`is a multi-physics finite element solver designed for computational modeling of the cardiovascular system. It is a major component of the on...
This repository contains Matlab code for data loaders, undersampling functions, evaluation metrics, and reference implementations of simple baselin...
Internship project of the Bioengineering career of the University of Antioquia for developed a 3D reconstruction process in pediatric patients with...
Recent Preprints
2025 ESC/EACTS Guidelines for the management of valvular ...
# 2025 ESC/EACTS Guidelines for the management of valvular heart disease: Developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and th...
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Education Interactive and evidence-based educational resources in general cardiology and subspecialties to support your continuing medical education. See more European Society of Cardiology Ou...
2025 ESC/EACTS Guidelines for the management of valvular heart disease
Keywords Guidelines • European Society of Cardiology (ESC) • European Association for Cardio-Thoracic Surgery (EACTS) • Valvular heart disease • Aortic stenosis • Aortic regurgitation • Mitral ste...
Pocket Guidelines on Valvular Heart Disease
Non-coronary Cardiac Intervention **Publication Date:** 2025 **Chairperson**: Fabien Praz and Michael A.Borger Order Pocket Guidelines **Table of Content**
Section 1 - Key messages Section 2 - Gaps in evidence Table of contents European Heart Journal; 2025 - doi: 10.1093/eurheartj/ehaf194 ESSENTIAL MESSAGES FROM THE 2025 ESC/EACTS GUIDELINES FOR THE...
Latest Developments
Recent developments in cardiac valve disease research include the validation of less invasive treatment options such as transcatheter aortic valve replacement (TAVR), which has shown comparable long-term outcomes to open-heart surgery, including a 20% reduction in all-cause mortality at 5 years in lower-risk patients (Results 3, Results 9). Additionally, innovative trials are assessing the safety and efficacy of new valve devices like Perceval, and ongoing research aims to improve diagnosis, treatment, and patient outcomes, with initiatives from organizations like the American Heart Association focusing on timely diagnosis and care (Results 1, Result 4).
Sources
Frequently Asked Questions
What are the key echocardiography guidelines for cardiac chamber quantification?
Roberto M. Lang et al. (2015) updated recommendations for cardiac chamber quantification by echocardiography, addressing technological developments and practice changes, with 17399 citations. An earlier version by Lang et al. (2005) established standards jointly with the European Association of Echocardiography, cited 11253 times. These guidelines standardize measurements for left ventricular and chamber assessment.
How does transcatheter aortic-valve replacement compare to surgery?
In high-risk patients with severe aortic stenosis, transcatheter and surgical aortic-valve replacement showed similar 1-year survival rates, though with different periprocedural risks, per Smith et al. (2011) with 6206 citations. Leon et al. (2010) demonstrated TAVR reduced death and hospitalization rates versus standard therapy in non-surgical candidates. These findings from randomized trials guide treatment selection.
What do guidelines recommend for valvular heart disease management?
The ACC/AHA 2006 Guidelines by Bonow et al. outline management strategies for valvular heart disease patients, cited 8502 times. The 2017 ESC/EACTS Guidelines by Baumgartner et al. cover aortic stenosis, regurgitation, and surgical interventions. Upcoming 2025 ESC/EACTS Guidelines by Praz et al. address current evidence gaps and Heart Team approaches.
What role does echocardiography play in valve disease evaluation?
Guidelines like Lang et al. (2015) provide updated protocols for chamber quantification to assess valvular regurgitation. Schiller et al. (1989) standardized left ventricle quantitation by 2D echocardiography, with 8125 citations. These methods support prosthetic valve assessment and risk stratification.
What are common risk models in cardiac valve surgery?
EuroSCORE and other cardiac surgery risk models predict outcomes in valve procedures, as noted in the field description. Guidelines integrate these for patient selection in TAVR and SAVR. Studies like Leon et al. (2010) highlight their impact on high-risk cohorts.
Open Research Questions
- ? How do outcomes of TAVR versus SAVR evolve in lower-risk patients beyond high-risk cohorts studied in Smith et al. (2011)?
- ? What updates in chamber quantification address limitations in echocardiography for prosthetic valve regurgitation per Lang et al. (2015)?
- ? Which risk models best predict long-term outcomes in valvular surgery amid evolving patient profiles?
- ? How can Heart Team decisions optimize intervention timing for mitral and tricuspid regurgitation?
- ? What evidence gaps persist in managing congenital valve diseases, as targeted by recent Cedars-Sinai funding?
Recent Trends
The 2025 ESC/EACTS Guidelines for valvular heart disease by Fabien Praz et al. introduce updated recommendations on aortic stenosis, mitral regurgitation, and Heart Team management.
Startups secured funding: CroíValve from EIC Accelerator, Leaflet Solutions CAD 5.73M for transcatheter mitral replacement, Cardiac Dimensions $53M for regurgitation devices.
Cedars-Sinai received $26M to compare surgical and minimally invasive congenital valve treatments.
Research Cardiac Valve Diseases and Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cardiac Valve Diseases and Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers